AI and predictive models
ElevioSight is a unique predictive model designed to simulate the evolution of disease-area drug markets and competitive environments. Our data-driven simulations support strategic decision-making across clinical development, launch planning, and market access.
ElevioSight provides foresight from early clinical development to life cycle management indications. Our models inform your development and market access strategies with concrete, quantified simulations.
What is the optimal target population or treatment line to maximize value?
How should indications or treatment lines be sequenced for maximum impact?
Which asset choices will best contribute to overall portfolio value?
ElevioSight enables forward-looking scenario planning by modeling how clinical development decisions will impact pricing, revenue, volume, market share, and ultimately, profitability. ElevioSight leverages robust disease area and country-level insights.
ElevioSight models are regularly updated to reflect the latest changes in global policies, market dynamics, and pricing developments. Our models are tailored to a product’s specific attributes, including disease area, indication, and patient populations.
ElevioSight covers the top 10 global markets, with country-specific simulations. Each simulation is built on rules developed by our market access experts in collaboration with local payer advisors.
ElevioSight models can be leveraged in multiple situations. Here are real world examples of how our clients are using ElevoSight to develop winning strategies across the life cycle of their assets—maximizing revenues, profits, shareholder value, and patients benefits.
ElevioSight was used by a large pharmaceutical company to compare multiple indication options at an early development stage (phase 1). We were able to anticipate how competition and value will evolve across different patient sub-populations.
ElevioSight is leveraged by a major pharmaceutical company to assess all lifecycle management (LCM) options from phase 1 through phase 3. This includes optimizing the sequencing of indications and selecting the most promising sub-populations.
A leading Immunology drug, already launched in over 10 indications and continuing to expand into new disease areas, uses ElevioSight to simulate competitive scenarios. Our tool helps forecast how actions taken by other pharmaceutical companies may impact future revenues.
See also
